← All trials
NCT05991388
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2023
- Primary completion
- Oct 31, 2030
- Completion date
- Oct 31, 2032
- First posted
- Aug 14, 2023
- Last posted
- Aug 14, 2023
- Enrollment
- 210
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of BirminghamLead sponsor
- University of CambridgeOverall official - principal investigator
- Cancer Research UKCollaborator
- Fight Kids CancerCollaborator
- RegeneronCollaborator
- ADC Therapeutics SARLCollaborator
- University of BirminghamOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.